BCX4430 NDA Enabling CMC and Non-Clinical Toxicology Studies

Awarded Award Notice Posted

Solicitation number
Not on record
Agency
Immediate Office of the Secretary Department of Health and Human Services
Awarded
to Biocryst Pharmaceuticals Inc.
Set-aside
No set-aside

Opportunity facts

Contract number
HHSO100201500007C Federal contract award
NAICS code
541711 Research and Development in Biotechnology
PSC
Not on record

Notice details come from SAM.gov. Updated .

Notice text

As posted on SAM.gov.

Added: Mar 31, 2015 10:00 am

BCX4430, an inhibitor of viral RNA - dependent RNA polymerase (RdRp), is the lead compound in BioCryst's broad spectrum antiviral program to meet the need for an effective and broad-spectrum parental direct-acting antiviral medical countermeasure (MCM). The proposed activity takes into account the Ebola virus diease (EVD) outbreak in West Africa while advancing the development of BCX4430 toward an NDA filing. 

On GovTribe

Work this opportunity on GovTribe

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity
Try for free Login